Company Filing History:
7 out of 18 
2 out of 19 Years Active: 2004-2014
Title: Innovations by Paul Van Eerdewegh: Pioneering Research in Respiratory Diseases and Obesity
Introduction
Paul Van Eerdewegh, an accomplished inventor based in Weston, Massachusetts, has made significant contributions to the fields of genetics and biotechnology. With a remarkable portfolio of nine patents, his innovative work revolves around genetic sequences associated with respiratory diseases and obesity, paving the way for advancements in diagnostics and therapeutics.
Latest Patents
Among his latest patents, Van Eerdewegh's inventions include groundbreaking nucleotide and amino acid sequences that are linked to respiratory diseases, such as asthma, and conditions related to obesity. His discoveries focus on genes identified from human chromosome 12q23-qter. These patents encompass the nucleotide sequences of these genes, along with isolated nucleic acids and encoded peptides. Furthermore, his inventions extend to vectors and host cells that incorporate these nucleotide sequences, as well as antibodies that specifically bind to the associated polypeptides. Notably, these inventions aim to create methods and compositions for diagnostics and therapeutic applications for asthma and other related diseases.
Additionally, his patent related to human genes involved in respiratory diseases and obesity details isolated nucleic acids that comprise specific genes and their encoded proteins. It also includes expression vectors and host cells containing these genes, along with antibodies that target the corresponding proteins.
Career Highlights
Throughout his career, Paul Van Eerdewegh has held pivotal roles in prominent biotechnology firms, notably Oscient Pharmaceuticals Corporation and Genome Therapeutics Corporation. His work at these institutions has been integral in advancing research related to genetic disorders and therapeutic interventions.
Collaborations
In his quest for innovation, Van Eerdewegh has collaborated with notable professionals such as Tim Keith and Randall D. Little. These partnerships have helped enhance the scope and impact of his research, resulting in fruitful contributions to the understanding of genetic influences on health.
Conclusion
Paul Van Eerdewegh exemplifies the spirit of innovation that drives biotechnology forward. His dedication to uncovering the genetic underpinnings of respiratory diseases and obesity has opened new avenues for therapeutic development. With his impressive body of work and collaborations, Van Eerdewegh continues to be a key figure in the realm of genetic research, making significant strides toward improved health outcomes.